FDA Orange Book · active-ingredient family
Retapamulin
Retapamulin is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:ALTABAX · NDA 022055
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · ointment
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ALTABAXRLD | ALMIRALL | NDA 022055 | — | Apr 12, 2007 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7875630 | Feb 14, 2027 | in 8 mo | Substance |
Retapamulin — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
